Clinical Fellowships
Alnylam's Clinical Fellowship Grant funds U.S. academic programs to train physicians in multidisciplinary care and research for Transthyretin-mediated Amyloidosis (ATTR).
Funder: Alnylam Pharmaceuticals
Due Dates (Anticipated): August 2026 (Clinical Fellowships)
Funding Amounts: Up to $95,000 USD per institution for a one-year clinical fellowship; funds support fellow salary and benefits only.
Summary: Supports U.S. academic programs training physicians in Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) through multidisciplinary clinical fellowships.
Key Information: Forecasted deadline—dates are projected; eligibility limited to ACGME-accredited U.S. institutions with active cardiology fellowship programs.
Description
Alnylam Pharmaceuticals offers Clinical Fellowship Grants to U.S. academic healthcare organizations focused on mentoring and advancing physician training in the diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The program is designed to foster multidisciplinary collaboration, improve early recognition of ATTR, optimize treatment pathways, and accelerate the translation of emerging science into high-quality, patient-centered care. Funding supports the salary and benefits of fellows engaged in a structured curriculum that includes multidisciplinary training, skill development, clinical care, research activities, and effective assessment methods.
